Clinical Trial Search

Primary: Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8 — 10.9; 13.3; 11.6; 13.8 percentage of…

Primary: Incidence of Adverse Events, Including Injection Site Reactions — 309.8; 312.7 Event rate per 100 patient years

Primary: WOMAC Pain Sub-score — -26.49; -27.33; -22.73 score on a scale

Primary: Dactylitis Severity Score (DSS) — -2; -5 change of score on a scale — p==0.026

Primary: Percent Change in the Number of Inflamed Lesions (Papules/Pustules)- Time Frame: Baseline to 12 Weeks — -66.22; -72; -16.02 % mean change from baseline

Primary: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Positive (Tumor Proportion Score [TPS] ≥50%) Tumors — 12.3; 10.9 Months — p=0.1276

Primary: Change From Baseline in A1C at Week 20 — -0.58; -0.09 Percentage of glycated hemoglobin — p== 0.018

Primary: Overall Survival — 50; 61; 116; 105 Participants — p=0.18

Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 40; 13…

Primary: Number of Days Subjects Received Treatment in Each Treatment Arm — 290; 325.3; 369.4; 222.36 Days

Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants

Primary: Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period — 43.3; 59.6…

Primary: Percentage Change in LDL-C From Baseline to Day 510 — -56.34; 1.30 percent change — p=<.0001

Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 33; 8…

Primary: Percentage of Participants With Adverse Events (AEs) Associated With Long-Term Exposure to Ambrisentan — 90.7 percentage of participants